2021
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19
Klein IA, Rosenberg SM, Reynolds KL, Zubiri L, Rosovsky R, Piper-Vallillo A, Gao X, Boland G, Bardia A, Gaither R, Freeman H, Kirkner GJ, Rhee C, Klompas M, Baker MA, Wadleigh M, Winer EP, Kotton CN, Partridge AH. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. The Oncologist 2021, 26: 685-693. PMID: 33856099, PMCID: PMC8251362, DOI: 10.1002/onco.13794.Peer-Reviewed Original ResearchConceptsHistory of cancerIndependent risk factorDeath/hospiceSevere COVID-19Survivors of cancerHospitalized patientsCancer historyActive cancerRisk factorsCurrent cancer diagnosisCancer diagnosisCOVID-19Laboratory-confirmed COVID-19Intensive care unit admissionCare unit admissionOdds of intubationCancer-directed therapySystemic cancer therapyStandard anticancer therapiesRecent cancer treatmentUnit admissionHospice admissionMedian ageMedian timeMultivariable analysis
2010
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress In Cardiovascular Diseases 2010, 53: 94-104. PMID: 20728696, DOI: 10.1016/j.pcad.2010.05.006.Peer-Reviewed Original ResearchConceptsCardiac adverse effectsCardiac toxicityCardiovascular toxicityNew drug developmentLeft ventricular ejection fraction declineVentricular ejection fraction declineAdverse effectsClassic chemotherapy agentsEjection fraction declinePotential cardiovascular toxicityRare serious complicationsNovel biologic agentsSignificant cardiac dysfunctionAcute coronary syndromeCongestive heart failureLong-term complicationsTypes of malignanciesSystemic cancer therapyLife-threatening eventsCancer therapyTyrosine kinase inhibitorsDrug developmentCardiovascular safetyCoronary syndromeBiologic agents